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Loss of epithelial cell identity and acquisition of mesenchymal features are early events in the neoplastic transformation of
mammary cells. We investigated the pattern of expression of a selected panel of genes associated with cell polarity and apical
junction complex or involved in TGF-β-mediated epithelial-mesenchymal transition and cell-fate decision in a series of DCIS
and corresponding patient-matched normal tissue. Additionally, we compared DCIS gene proﬁle with that of atypical ductal
hyperplasia(ADH)fromthesamepatient.Statisticalanalysisidentiﬁeda“core”ofgenesdiﬀerentiallyexpressedinbothprecursors
with respect to the corresponding normal tissue mainly associated with a terminally diﬀerentiated luminal estrogen-dependent
phenotype,inagreementwiththemodelaccordingtowhichER-positiveinvasivebreastcancerderivesfromER-positiveprogenitor
cells, and with an autocrine production of estrogens through androgens conversion. Although preliminary, present ﬁndings
provide transcriptomic conﬁrmation that, at least for the panel of genes considered in present study, ADH and DCIS are part
of a tumorigenic multistep process and strongly arise the necessity for the regulation, maybe using aromatase inhibitors, of
the intratumoral and/or circulating concentration of biologically active androgens in DCIS patients to timely hamper abnormal
estrogens production and block estrogen-induced cell proliferation.
1.Introduction
Ductal carcinoma in situ (DCIS), also known as intraductal
carcinoma, is the most common type of noninvasive breast
cancer in women [1]. From the mid-1970s, the incidence
of DCIS has sharply increased, primarily because of the
adoption of radiographic screening for invasive carcinoma.
Currently, it accounts for approximately 25% of newly
diagnosed breast cancer cases [1].
DCISisanonobligateprecursortoinvasivebreastcancer,
and for this reason some members of the 2009 US National
Institutes of Health DCIS consensus conference proposed
to remove the word “carcinoma” from the term DCIS [2].
Nevertheless, experimental studies have shown the presence
of carcinoma precursor cells in DCIS lesions [3–5], and
clinical evidence indicates that approximately 50% of cases
will progress to invasive breast cancer if untreated [6, 7].
As a result, the malignant nature of DCIS remains debated,
primarily because of the limited knowledge of DCIS arising
and development. In fact, while several genome-wide studies
have compared the gene proﬁles of DCIS and invasive breast
cancer, very few studies have investigated and recognized the
molecular alteration that characterize DCIS with respect to
normal tissue [8–11].
DCIS is deﬁned as an abnormal proliferation of trans-
formed mammary epithelial cells within the closed envi-
ronment of a duct, likely in response to microenvironment
alterations including hypoxia and nutrient deprivation [4,
12]. Among the processes early aﬀected during mammary
cells transformation, those involved in the establishment and
maintenance of epithelial cell identity and tissue speciﬁcity
are of particular relevance. In fact, epithelial mammary cells
are characterized by an asymmetric distribution of cytoplas-
mic and membrane proteins, termed apicobasolateral cell2 International Journal of Surgical Oncology
polarity, essential for a correct cell-cell adhesion and the
formation of an epithelial sheet. As a result of an epithelial to
mesenchymal transition (EMT), during neoplastic transfor-
mation, cell polarity and epithelial morphology are early lost
polarized and immotile epithelial cells acquire a ﬁbroblast-
like morphology and increased cell motility [13].
EMT process can be induced by a variety of signaling
pathways among which the main and best characterized
is that involving transforming-growth factor-β (TGF-β).
TGF-β is a multifunctional cytokine and a powerful tumor
suppressorthatgovernsmanyaspectsofmammaryepithelial
cells physiology and homeostasis [14]. Under abnormal
microenvironment conditions; however, some mammary
epithelial cells may acquire resistance to TGF-β,c i r c u m v e n t
its cytostatic eﬀect and tumor suppressive activity, and
activate EMT [15, 16].
Recent studies have demonstrated that EMT may gen-
erate cells with stemness-like properties, especially in the
transitioning mammary epithelial cell compartment [17,
18]. Therefore, a interrelationship among EMT (TGF-β
mediated), disruption of the mechanisms deputed to cell
polarity and adhesion control, and acquisition of stemness-
like features can be assumed already in DCIS [19, 20].
Taking advantage from the only microarray dataset
publicly accessible at the ArrayExpress web site, we inves-
tigated the pattern of expression of a selected panel of
genes involved in TGF-β-mediated EMT or associated with
epithelial cells identity (i.e., cell polarity and apical junction
complex) and cell-fate decision in a series of DCIS and
corresponding patient-matched histologically normal (HN)
epithelium [11]. As the whole-gene expression proﬁle of
patient-matched atypical ductal hyperplasia (ADH) was also
available, we further compared DCIS and ADH proﬁles
to verify the hypothesis according to which breast cancer
progression is a multistep process involving a continuum
of changes from normal phenotype through hyperplastic
lesions, carcinoma in situ, and invasive carcinoma [21].
2.MaterialsandMethods
2.1. Materials. As reported in the original paper [11],
patient-matched samples (HN, ADH, and DCIS) were
isolated via laser capture microdissection from surgical
specimens of 12 preoperative untreated patients with an
ER-positive (immunohistochemically evaluated) sporadic
breast cancer. Gene expression was determined by using the
Aﬀymetrix Human Genome HG-U133A GeneChip; corre-
sponding microarray dataset was publicly available at the
ArrayExpress web site (http://www.ebi.ac.uk/arrayexpress/)
with the Accession number E-GEOD-16873.
2.2. Gene Selection. To select the panel of genes speciﬁcally
involved in the TGF-β-activated EMT, cell polarity and
apical junction complex, and cell-fatedecision, we combined
Gene Ontology (http://www.geneontology.org)a n dP u b M e d
(http://www.ncbi.nlm.nih.gov) information. In addition,
sincecancercellsoftenincreasetheirautocrineproductionof
TGF-β to activate angiogenesis in response to oxygen and
nutrients deprivation [14], we also included some genes
coding forangiogenesis-inducing factors.Onthe whole,aset
of 199 genes evolutionarily conserved in Homo sapiens was
established (see Supplementary Table 1 available on line at
doi 10.1155/2012/984346). However, because 27 genes had
no corresponding probe-sets on the HG-U133A GeneChip,
the gene set was actually composed of 172 elements, 33
of which involved in EMT activation [13–15, 21–23], 75
involved in cell polarity and apical junction assembly [24–
26], 36 involved in cell fate-decisions and in the maintenance
of a self-renewal state in tumorigenic adult tissues [27–
29], 28 involved in hormone steroid signaling [30–32],
angiogenesis activation [33, 34] or used as luminal and
basal markers [35–38]. These 172 genes corresponded to
339 Aﬀymetrix probe-sets, as veriﬁed by GeneAnnot system
v2.0 (http://bioinfo2.weizmann.ac.il/geneannot/), that addi-
tionally provided us information about the quality of each
probe-setintermsofsensitivityandspeciﬁcityscore[39](see
Supplementary Table 2).
2.3. Statistical Analysis. As some genes are recognized by
more than a single probe set, each of which characterized
by an individual speciﬁcity and sensitivity that diﬀerently
contribute to gene expression value, a gene expression mean
value was calculated after weighting each probe-set for its
own sensitivity and speciﬁcity score. Speciﬁcally, each ex-
pression value (already log 2 transformed in the original
dataset) was multiplied for the semi sum of sensitivity and
speciﬁcity scores of the corresponding probe set. Given the
patient-matched samples study design, all statistical analyses
were performed considering a regression model for repeated
measures with random eﬀect, and the diﬀerential gene ex-
pression was evaluated by t-test on regression coeﬃcients. To
correct for multiple testing, the false discovery rate (FDR)
was used [40].
To evidence latent variables accounting for genes correla-
tions, a factoranalysiswasapplied [41] in thefollowingthree
comparisons: DCIS and paired ADH, DCIS and paired HN,
and ADH and paired HN. The number of retained factors
was selected according to the scree test [42]. To facilitate the
interpretation of the factors, varimax rotation was applied.
Loading values lower than 0.3 were not considered.
A l la n a l y s e sw e r ep e r f o r m e du s i n go p e ns o u r c es o f t w a r e
R 2.11.1 packages HDMD (http://www.R-project.org).
3. Results and Discussion
Genes found diﬀerentially expressed (P<0.05) between
DCIS and NH or ADH and NH are reported in Table 1.
Speciﬁcally, 47 of the 172 selected genes were found diﬀeren-
tiallyexpressed betweenDCISandNH(11withanestimated
FDR < 0.01) and 28 were found diﬀerentially expressed
between ADH and NH (only one with an estimated FDR <
0.01). Notably, 24 of the 28 genes found diﬀerentially ex-
pressed between ADH and NH were found diﬀerentially
ex-pressed (in a similar manner) also between DCIS and
NH. The persistence of this “core” of genes, dysregulated in
a similar manner in both invasive breast cancer precursors,International Journal of Surgical Oncology 3
Table 1: Diﬀerentially expressed genes between ADH or DCIS and histologically normal (HN) tissue (ordered according to P value).
ADH versus HN DCIS versus HN
Gene symbol P value Variation Gene symbol P value Variation
JAM3 0.000045 ↓ JAM3 0.000016 ↓
JAG2 0.000337 ↓ EGFR 0.000103 ↓
CD24 0.000364 ↑ SNAI2 0.000127 ↓
SNAI2 0.000594 ↓ CLDN5 0.000136 ↓
EGFR 0.001897 ↓ JAM2 0.000150 ↓
FOXC1 0.002222 ↓ FOXC1 0.000167 ↓
EGF 0.003163 ↓ CD24 0.000277 ↑
ID2 0.003547 ↑ JAG2 0.000297 ↓
JAM2 0.005052 ↓ KRT5 0.000420 ↓
TJP3 0.005070 ↑ KRT14 0.000425 ↓
TGFBR3 0.005537 ↓ GATA3 0.000490 ↑
KRT17 0.005624 ↓ TGFBR3 0.000710 ↓
GATA3 0.005795 ↑ TJP3 0.001046 ↑
TP53 0.006737 ↑ KRT17 0.001402 ↓
CDH4 0.006916 ↓ SOX4 0.001942 ↑
AKT1 0.009044 ↑ AKT1 0.002867 ↑
CLDN7 0.012026 ↑ CLDN8 0.003090 ↓
EPCAM 0.015207 ↑ CDC42 0.003643 ↑
ABCG2 0.019210 ↓ EGF 0.003752 ↓
KRT5 0.019854 ↓ EPCAM 0.004605 ↑
KRT14 0.020117 ↓ CLDN7 0.004749 ↑
CLDN11 0.023005 ↓ ESR1 0.007188 ↑
PARD3 0.030202 ↓ DLG1 0.007249 ↑
SOX4 0.036127 ↑ KRT19 0.007637 ↑
CDC42 0.036404 ↑ FOXA1 0.007844 ↑
TIAM1 0.038034 ↑ KRT18 0.010091 ↑
ESR1 0.038527 ↑ CDH3 0.010638 ↓
PVR 0.039104 ↓ TIAM1 0.010722 ↑
TGFBR2 0.013243 ↓
RHOA 0.013540 ↑
BRCA1 0.014098 ↑
ID4 0.017030 ↓
ID2 0.018115 ↑
NOTCH4 0.018550 ↓
PVRL2 0.019914 ↑
AKT3 0.020275 ↓
ACTN1 0.020619 ↓
PROM1 0.022238 ↓
CDH4 0.022933 ↓
DLG3 0.023798 ↑
F11R 0.031657 ↑
CTNNA1 0.033234 ↑
MTA2 0.033999 ↓
ABCG2 0.037966 ↓
MPP5 0.039023 ↑
HIF1A 0.039489 ↑
CDKN1A 0.047769 ↑
In bold, genes with an estimated FDR < 0.01.4 International Journal of Surgical Oncology
seems to support the hypothesis of ADH as the direct
precursor of DCIS. In fact, in agreement with the proposed
multistep process, DCIS showed an increased number of
genes diﬀerentially expressed with respect to ADH.
With respect to normal tissue, both DCIS and ADH
showed the overexpression of ESR1, coding for the estro-
gen receptor; CD24, coding for a mucin-like cell-adhesion
molecule positively associated with a terminally diﬀeren-
tiated luminal phenotype [43, 44]; GATA3, coding for a
transcription factor involved in mammary gland morpho-
genesis [35, 36]; CLDN7, EPCAM, and TJP3, coding for
tight junction components; CDC42 and TIAM1, coding for
two small GTPase family members involved in cell polarity
and apical junction complex formation. Concomitantly,
both breast cancer precursors showed the underexpression
of EGFR gene, in which expression is generally negatively
associated with ESR1 expression, KRT5, KRT14, and KRT17,
allcoding for cytokeratins associated with a basal phenotype.
On the whole, this pattern of expression clearly indicates
that DCIS and ADH are both characterized by a terminally
diﬀerentiated luminal phenotype. Since all specimens were
derived from patients with an ER-positive ductal carcinoma,
it is conceivable the hypothesis that the establishment of
an estrogen-dependent phenotype, in response to estrogens
present in the microenvironment, should be a very early
event in the tumorigenic process. Such a ﬁnding is in
agreement with the model for breast cancer development
proposed by Dontu et al. [45], according to which ER-
positive cancers should derive from transiently amplifying
ERpositive progenitor cells. Escaped from proliferation
control as a consequence of genetic and epigenetic alter-
ations in genes involved in cell-fate decision, these ER-
positive progenitor cells should generate cells constitutively
expressing estrogen receptor. Once established in ADH,
this terminally diﬀerentiated luminal phenotype seems to
consolidate in DCIS as demonstrated by the presence,
among the genes exclusively expressed in DCIS, of KRT18,
KRT19 (coding for some luminal-associated cytokeratins)
and DLG1, DLG3, and MPP5 (coding for some cell polarity
complex components).
With respect to both tumor precursors, histologically
normal tissue expressed genes coding for some transcription
factors involved in EMT (SNAI2 and TGFBR3) and cell-fate
decision (FOXC1 and JAG2), and for stemness-associated
features (ABCG2). This ﬁnding is more evident considering
the 47 genes diﬀerentially expressed between DCIS and
normal tissue among which we found some other genes
involved in the TGF-β-mediated EMT (AKT3, ID4 and
TGFBR2), and cell-fate decision and self-renewal (NOTCH4
and PROM1).
Such an apparently paradoxical ﬁnding, that is, the
positive association between histologically normal tissues
and EMT- and stemness-related genes (more likely expected
in transformed tissues) is not surprising since we observed a
similar behavior in an independent cases series composed of
primary breast cancers and corresponding patient-matched
normal tissue (submitted paper) and in normal pleura with
respect to pleural mesothelioma [46]. In agreement with
the physiological remodeling of the mammary gland,
such a ﬁnding should support the persistence of resident
stem/progenitor cells in normal tissue [47, 48].
Factor analysis, applied to investigate the latent variables
intrinsically associated with the selected 172 genes, corrobo-
rated these ﬁndings and highlighted some other interesting
interrelations. In agreement with the results provided by t-
paired test, factor analysis indicated that in both precursors
(Figure 1(a) for DCIS and Figure 2(a) for ADH), the ﬁrst
factor (F1) was principally characterized by genes associated
with an estrogen-dependent epithelial phenotype. In fact,
within the genes with a positive loading value on F1, we
found those coding for hormone steroid receptors (AR
and ESR1) and transcriptional coactivator for steroid and
nuclear hormone receptors (NCOA1), for tight (EPCAM,
MAGI1, MAGI2, MPDZ, TJP1, TJP2 and TJP3) and adherens
(CTNND1, PFN1 and PVRL2) junction components, and
for small GTPase family members involved in epithelial cell
polarization processes (CDC42 and RHOA). In addition, we
found some genes associated with cell-fate decision: BMI-
1, coding for a member of Polycomb group required to
maintain the transcriptionally repressive state of many genes
throughout embryo development [49] and adult tissues
diﬀerentiation including mammary gland [50]; FDZ4 and
FDZ6, two members of the frizzled gene family involved in
β-catenin-signaling transduction and intercellular transmis-
sion of polarity information in diﬀerentiated tissues [51].
Furthermore, in agreement with the notion that ERα,
and TGF-β-signaling pathways are major regulators during
mammary gland development [52], we found genes coding
for TGF-β receptor (TGFBR3) or for proteins involved in
canonical (ID1, SMAD2 and SMAD4) and noncanonical
(PTEN, RHOA and ROCK1)T G F - β pathways [15, 16].
Finally, probably associated with the adaptation of DCIS
and ADH to hypoxic stress caused by the unbalance between
cell proliferation and oxygen supply, we also found JAM2,
JAM3, VEGFA, VEGFB, and VEGFC, all genes involved in
endothelial cell proliferation.
The second factor (F2) identiﬁed by factor analysis
(Figure 1(b) for DCIS and Figure 2(b) for ADH) was con-
versely characterized by the positive loading value of several
genes coding for mesenchymal markers (EGF, EGFR, KRT5,
KRT6B, KRT14 and KRT17), and the negative loading value
of GATA3, the gene coding for the transcription factor
driving the luminal morphogenesis of the mammary gland
[35, 36]. In addition, F2 was characterized by the presence
of some genes coding for proteins playing a critical role
in cell-fate decision and cell-renewal (ALDH1A3, FOXC1,
NOTCH2, PROM1, and SOX9)[ 53].
Notably, when applied to ADH subgroup, factor analysis
identiﬁed CYP19A1 as included in the panel of genes char-
acterizing the ﬁrst factor. This gene encodes for cytochrome
P450 (better known as aromatase), the enzyme that catalyzes
the conversion from circulating and rostenedione to estrone
or testosterone to estradiol, and its presence should support
the hypothesis of a very early activation of an autocrine
production of estrogen. Furthermore, the concomitant pres-
ence of CYP19A1, AR, ESR1, and NCOA1 should provide
a transcriptomic conﬁrmation for the clinical evidence that
high androgens level may have detrimental eﬀect on breastInternational Journal of Surgical Oncology 5
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Figure 1: Factor analysis in DCIS subgroup. Schematic representation of genes with a loading value < |0.6| characterizing the ﬁrst
(F1) and the second factor (F2). Solid color indicates a positive loading value whereas dashed color indicates a negative loading value.
Color correspondence: light yellow, tight junction components; dark yellow, adherens junction components; light blue, polarity complexes
components; dark blue, angiogenesis; orange,c e l l - f a t ed e c i s i o n ;light green, luminal markers and hormone steroid; dark green, basal markers;
pink, epithelial-mesenchymal transition, grey, GTPase family members.6 International Journal of Surgical Oncology
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Figure 2: Factor analysis in ADH subgroup. Schematic representation of genes with a loading value < |0.6| characterizing the ﬁrst
(F1) and the second factor (F2). Solid color indicates a positive loading value whereas dashed color indicates a negative loading value.
Color correspondence: light yellow, tight junction components; dark yellow, adherens junction components; light blue, polarity complexes
components; dark blue, angiogenesis; orange,c e l l - f a t ed e c i s i o n ;light green, luminal markers and hormone steroid; dark green, basal markers;
pink, epithelial-mesenchymal transition, grey, GTPase family members.International Journal of Surgical Oncology 7
carcinogenesis and progression due to a persistent local es-
trogen production that incessantly stimulates epithelial cell
proliferation [54–56].
WhenappliedtoDCISsubgroup,factoranalysisseemsto
indicate a consolidation of such an estrogen dependence as
suggested by the additional presence of PGR, the gene coding
for progesterone receptor and which expression is under
estrogenic control.
4. Conclusions
Elucidating the initial steps of breast tumorigenesis is of
paramount importance to allow an even early diagnosis and
consequently an adequate treatment strategy aimed to pre-
vent the malignant transformation of preneoplastic alter-
ations. That is of particular importance for DCIS because of
its high incidence [1] and facility in progressing to invasive
breast cancer if untreated [6, 7].
Experimental evidence till now accumulated has clearly
indicated that at the basis of the neoplastic transformation
of mammary epithelial cells there are loss of apicobasal
epithelial cell identity and acquisition of a functional mes-
enchymal morphology. Therefore, we investigated the pat-
tern of expression of a selected panel of genes associated with
epithelial cells identity (i.e., cell polarity and apical junction
complex) or involved in TGF-β- m e d i a t e dE M Ta n dc e l l -
fate decision in a series of DCIS and corresponding patient-
matched normal tissue. In addition, we compared DCIS
proﬁle with that of patient-matched ADH to investigate the
hypothesis according to which breast cancer progression is
a multistep process involving a continuum of changes from
normal phenotype through hyperplastic lesions, carcinoma
in situ, and invasive carcinoma [21].
Statistical analysis seems to support this hypothesis
because it identiﬁed a “core” of genes, mainly associated
with a terminally diﬀerentiated luminal phenotype, and dif-
ferentially expressed in both precursors with respect to the
corresponding normal tissue. Notably, these alterations in
gene expression did not result in a progressive mesenchymal
transition but rather in a terminally diﬀerentiated luminal
phenotype, in agreement with the model according to
which ER-positive invasive breast cancer derives from ER-
positive progenitor cells [45]. The constitutive expression
of ER should make ADH and DCIS forming cells able
to exploit the proliferative stimulus induced by estrogens
whereas the establishment of an autocrine production of
estrogens, through androgens conversion, should provide an
additional selective advantage. The detrimental eﬀect of such
continuous estrogen stimulation should be corroborated by
theobservationthatallpatientsincludedinthepresentstudy
developed an invasive ER-positive ductal carcinoma.
Experimental evidence supporting the hypothesis that
androgens conversion may be involved in DCIS devel-
opment, and progression has been provided by a recent
study in which the intratumoral concentration of estradiol
and 5α-dihydrotestosterone (DHT), and the expression of
some sex steroid-producing enzymes, including aromatase,
has been evaluated in DCIS specimens [57]. The study
clearly demonstrated that aromatase expression level was
signiﬁcantly higher in DCIS with respect to nonneoplastic
tissue suggesting the self-sustaining process adopted by
DCIS.
Taken together all these ﬁndings provide transcriptomic
conﬁrmation that, at least for the panel of genes considered
in present study, ADH and DCIS are part of a tumorigenic
multistep process and strongly arise the necessity for the
regulation, maybe using aromatase inhibitors, of the intratu-
moral and/or circulating concentration of biologically active
androgens in DCIS patients to timely hamper abnormal
estrogens production and block estrogen-induced cell pro-
liferation [58].
There is no doubt that present in silico study suﬀers for
the limitation common to the majority of studies involving
gene expression proﬁle, that is, the lack of validation, at
protein level, of the modulations observed at mRNA level.
In fact, it is well known that mRNA transcript levels do
not always reﬂect protein expression. However, the immun-
ohistochemical data provided in The Human Protein Atlas
largely conﬁrms the diﬀerential gene expression that we
observed between histologically normal and cancerous tis-
sue. For instance, when we considered the 11 genes with
an estimated FDR < 0.01 (Table 1, in bold), we found
that protein expression of normal breast (glandular cell)
and breast cancer tissue mainly paralleled the mRNA dif-
ferential expression we observed in our dataset, making our
preliminary ﬁndings more reliable and worthy of further
investigation.
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